Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11909985 | 0.86 | FLT3 (0.34) | ALDH1A1KMT2ATSHRMAPK1HSD17B10 | |
| SCHEMBL15155092 | 0.81 | ALDH1A1 (0.39) | ALDH1A1KMT2ATSHRMAPK1HSD17B10 | |
| SCHEMBL27711333 | 0.80 | L3MBTL1 (0.44) | ALDH1A1KMT2ATSHRMAPK1HSD17B10 | |
| SCHEMBL26598687 | 0.79 | ALDH1A1 (0.35) | ALDH1A1KMT2ATSHRMAPK1HSD17B10 | |
| SCHEMBL12093594 | 0.78 | LMNA (0.39) | ALDH1A1KMT2ALMNAJAK2JAK1 | |
| SCHEMBL670006 | 0.78 | — | — | |
| SCHEMBL20257886 | 0.77 | JAK2 (0.35) | JAK2JAK1TYK2JAK3ALOX5AP | |
| SCHEMBL1703246 | 0.77 | MAPT (0.41) | ALDH1A1KMT2AMAPTPKMLMNA | |
| SCHEMBL5199006 | 0.77 | JAK2 (0.35) | JAK2JAK1TYK2JAK3ALOX5AP | |
| SCHEMBL1872520 | 0.76 | MAOB (0.50) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4482832-A1 | 5-[7-(3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBONYL)-1,2,3,4 TETRAHYDROISOQUINOLIN-6-Y L]-1H-PYRROLE-3-CARBOXAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | Les Laboratoires Servier (FR) | 2025-01-01 | — | — | EP | disclosed |
| WO-2023161317-A1 | 5-[7-(3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBONYL)-1,2,3,4 TETRAHYDROISOQUINOLIN-6-Y L]-1H-PYRROLE-3-CARBOXAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2023-08-31 | — | — | WO | disclosed |
| US-10391082-B2 | Protein kinase inhibitors | ORION CORPORATION (FI) | 2019-08-27 | — | — | US | disclosed |
| US-20180250272-A1 | PROTEIN KINASE INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-09-06 | — | — | US | disclosed |
| US-20160346254-A1 | PROTEIN KINASE INHIBITORS | ORION CORP (FI) | 2016-12-01 | — | — | US | disclosed |
| US-9447091-B2 | Protein kinase inhibitors | ORION CORPORATION (FI) | 2016-09-20 | — | — | US | disclosed |
| EP-2766354-B1 | PROTEIN KINASE INHIBITORS | ORION CORP (FI) | 2016-05-18 | — | — | EP | disclosed |
| US-20150011548-A1 | PROTEIN KINASE INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2015-01-08 | — | — | US | disclosed |
| US-8697725-B2 | Tetrahydroquinoline derivatives and their pharmaceutical use | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-8697725-B2 | Tetrahydroquinoline derivatives and their pharmaceutical use | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120035164-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-02-09 | — | — | US | disclosed |
| US-8063071-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2011054841-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2010007756-A1 | PYRIDINE DERIVATIVE HAVING TTK INHIBITION ACTIVITY | 塩野義製薬株式会社 (JP) | 2010-01-21 | — | — | WO | disclosed |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-06-04 | — | — | US | disclosed |
| CN-101247804-A | chemical compound | SMITHKLINE BEECHAM CORP (US) | 2008-08-20 | — | — | CN | disclosed |
| EP-1896014-A2 | CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007005534-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035164-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | ALDH1A1 2634/4885KMT2A 629/4885TSHR 3204/4885 |
| US-20150011548-A1 | PROTEIN KINASE INHIBITORS | FGFR1, FGFR3, FGFR4 | ALDH1A1 3331/4885KMT2A 1203/4885TSHR 1818/4885 |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | ABCB1, CYP3A7, UGT2B7 | ALDH1A1 852/4885KMT2A 1698/4885TSHR 3623/4885 |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | ALDH1A1 2634/4885KMT2A 629/4885TSHR 3204/4885 |
| US-20160346254-A1 | PROTEIN KINASE INHIBITORS | FGFR1, FGFR3, FGFR4 | ALDH1A1 3331/4885KMT2A 1203/4885TSHR 1818/4885 |
| US-20180250272-A1 | PROTEIN KINASE INHIBITORS | FGFR1, FGFR3, FGFR4 | ALDH1A1 3196/4885KMT2A 1221/4885TSHR 1845/4885 |
| US-10391082-B2 | Protein kinase inhibitors | FGFR1, FGFR3, FGFR4 | ALDH1A1 3196/4885KMT2A 1221/4885TSHR 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.